Atara Biotherapeutics (ATRA) Total Current Liabilities (2013 - 2026)

Atara Biotherapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 88.21% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (down 88.21% YoY), and the FY2025 full-year result was $14.9 million, down 88.91% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.6 million, down from $14.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $180.7 million in Q1 2024, with the low at $5.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $82.5 million across 5 years, with a median of $74.6 million in 2023.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 166.21% — and 2025, when it sank 90.18%.
• Atara Biotherapeutics' Total Current Liabilities stood at $78.9 million in 2022, then jumped by 80.22% to $142.2 million in 2023, then dropped by 5.38% to $134.6 million in 2024, then sank by 88.91% to $14.9 million in 2025, then plunged by 62.17% to $5.6 million in 2026.
• The last three Total Current Liabilities figures came in at $5.6 million (Q1 2026), $14.9 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.